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Background: Patients with melanoma and negative sentinel nodes (SNs) have varying outcomes, depen-
dent on several prognostic factors. Considering all these factors in a prediction model might aid in
identifying patients who could benefit from a personalized treatment strategy. The objective was to con-
struct and validate a nomogram for recurrence and melanoma-specific mortality (MSM) in patients with
melanoma and negative SNs.
Methods: A total of 3220 patients with negative SNs were identified from a cohort of 4124 patients from
four EORTC Melanoma Group centres who underwent sentinel lymph node biopsy. Prognostic factors
for recurrence andMSMwere studied with Cox regression analysis. Significant factors were incorporated
in the models. Performance was assessed by discrimination (c-index) and calibration in cross-validation
across the four centres. A nomogram was developed for graphical presentation.
Results: There were 3180 eligible patients. The final prediction model for recurrence and the calibrated
model for MSM included three independent prognostic factors: ulceration, anatomical location and
Breslow thickness. The c-index was 0⋅74 for recurrence and 0⋅76 for the calibrated MSM model.
Cross-validation across the four centres showed reasonable model performance. A nomogram was
developed based on these models. One-third of the patients had a 5-year recurrence probability of 8⋅2
per cent or less, and one-third had a recurrence probability of 23⋅0 per cent or more.
Conclusion: A nomogram for predicting recurrence and MSM in patients with melanoma and negative
SNs was constructed and validated. It could provide personalized estimates useful for tailoring surveil-
lance strategies (reduce or increase intensity), and selection of patients for adjuvant therapy or clinical
trials.
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Introduction
Sentinel lymph node biopsy (SLNB), introduced in 1991
as a staging procedure for cutaneous melanoma, evalu-
ates the presence of lymph node involvement1. The impact
of SLNB has been studied extensively and is one of
the most important prognostic indicators for recurrence
and survival in patients with melanoma2,3. Consequently,
sentinel node (SN) status has significant implications for
treatment strategy. Patients with a positive SN usually had
completion lymph node dissection (CLND), but the land-
mark DeCOG-SLT trial4 and Multicenter Selective Lym-
phadenectomy Trial (MSLT) II trial5 concluded there was
no significant survival benefit for CLND compared with
nodal observation. In future, most patients with positive
SNs will be offered routine adjuvant therapy, conceivably
without preceding CLND4–9. Patients with negative SNs
have not been included in recent adjuvant therapy trials
© 2018 The Authors. BJS published by John Wiley & Sons Ltd on behalf of BJS Society Ltd. BJS
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any
medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
D. Verver, D. van Klaveren, V. Franke, A. C. J. van Akkooi, P. Rutkowski, U. Keilholz et al.
and are usually offered regular surveillance examinations
instead.
Reported recurrence rates for patients with negative SNs
vary between 6 and 29 per cent10,11. When accounting
for histological subtype and ulceration, the recurrence rate
may increase up to 43 per cent, which, strikingly, approx-
imates the recurrence rate in patients with positive SNs11.
Perhaps these high-risk patients with negative SNs might
benefit from adjuvant therapy as well.
The eighth edition of the AJCC staging manual cate-
gorizes melanoma with a negative SN into stages IA–IIC
based on ulceration and Breslow thickness (T category)12.
Several other independent factors have been identified that
contribute to risk of recurrence and/or melanoma-specific
mortality (MSM)13. Considering these additional clinico-
pathological factors in a prediction model might provide
more accurate patient-specific estimates that could be used
for treatment strategy decision-making. The objective of
the present study was to identify independent prognos-
tic factors in a large European melanoma population with
negative SNs to develop and validate a prediction model
for recurrence and MSM, presented in the form of a
nomogram.
Methods
Cohort characteristics
A retrospective cohort collected and described previously14
was used for this study. The cohort contained 4124 patients
who underwent a SLNB between 1997 and 2013 in one of
four European Organization for Research and Treatment
of Cancer (EORTC) Melanoma Group centres. The study
was approved and performed in accordance with local
ethics committee guidelines and national legislation. For
purposes of the present study, a total of 3220 patients with
a negative SN were identified from this cohort. Data on
sex, age, diagnosis date, date of SLNB, primary tumour
characteristics (Breslow thickness, ulceration), and details
on recurrence and follow-up were collected.
Procedures and follow-up
Histopathological examination of an excision biopsy of the
primary melanoma led to the diagnosis in all patients. The
excision biopsy was performed with total thickness exci-
sion and a narrow circumferential margin15. Eligibility for
SLNB in all centres was assessed according to international
guideline criteria: Breslow thickness greater than 1⋅0mm
or presence of risk factors, including ulceration, Clark level
IV or V according to the sixth edition of the AJCC staging
manual up to 200916, and regression ormitosis greater than
1/mm2 according to the seventh edition of the AJCC stag-
ing manual from 200917. In general, a wide local excision
was performed simultaneously with the SLNB, as described
elsewhere1,14. Histopathological analysis of the SN was
conducted according to the EORTC Melanoma Group
pathology protocol18. Follow-up strategies in EORTC
centres varied, but usually consisted of clinical examination
two to four times per year for 5–10 years15,19.
Outcomes
Outcomes of interest were recurrence and MSM, calcu-
lated from date of SLNB to date of first recurrence or
death. When there was multisite first recurrence, the site
with the worst prognosis was scored as the first site. Subse-
quently, recurrence was defined as new locoregional recur-
rence only: in-transit metastasis or satellites, regional nodal
recurrence in similar SN basin (with or without concurrent
locoregional disease), or distant nodal or systemic recur-
rence (with or without concurrent regional nodal and/or
locoregional disease). As the type of recurrence does not
have clinical consequences at first (all patients with recur-
rence will undergo several diagnostic tests anyway) and
to retain as much statistical power and as few method-
ological issues as possible, all recurrence was the out-
come used for the prediction model. Median follow-up
from date of SLNB to date of last follow-up was calcu-
lated, applying the reversed Kaplan–Meier method; deaths
were censored. Disease-free survival (DFS) was calculated
from date of SLNB to date of first recurrence; lost to
follow-up or death was censored. Melanoma-specific sur-
vival (MSS) was calculated from date of SLNB to date of
MSM; lost to follow-up or death from other causes was
censored.
Statistical analysis
The checklist proposed by the AJCC was used for guid-
ance in building a high-quality prediction model20. Associ-
ations between possible prognostic factors and recurrence
were studied with Cox regression analysis. The following
nine variables were identified as possible prognostic factors
based on clinical experience, literature review and avail-
ability of sufficient data: sex, age, ulceration, location, his-
tology, Breslow thickness, level of invasion (Clark level),
total number of SNs removed and multiple SN fields. To
make efficient use of the available data an advanced multi-
ple imputation of missing values strategy (5 imputations)
was applied21. The possible non-linearity of the contin-
uous variables (age, Breslow thickness and total number
of SNs removed) was modelled by logarithmic transfor-
mation. Independent prognostic factors were selected with
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Table 1 Baseline patient and tumour characteristics by centre
EORTC centres
All (n=3180) Centre 1 (n=398) Centre 2 (n=1082) Centre 3 (n=953) Centre 4 (n= 747)
Age (years)* 55 (44–67) 51 (40–62) 63 (49–71) 51 (42–62) 55 (44–65)†
Sex
F 1668 (52⋅5) 211 (53⋅0) 478 (44⋅2) 589 (61⋅8) 390 (52⋅2)
M 1510 (47⋅5) 187 (47⋅0) 604 (55⋅8) 364 (38⋅2) 355 (47⋅5)
Missing 2 (0⋅1) 0 (0) 0 (0) 0 (0) 2 (0⋅3)
Anatomical site
Arm 556 (17⋅5) 74 (18⋅6) 187 (17⋅3) 180 (18⋅9) 115 (15⋅4)
Leg 996 (31⋅3) 146 (36⋅7) 255 (23⋅6) 369 (38⋅7) 226 (30⋅3)
Trunk 1360 (42⋅8) 162 (40⋅7) 517 (47⋅8) 390 (40⋅9) 291 (39⋅0)
Head and neck 259 (8⋅1) 16 (4⋅0) 123 (11⋅4) 13 (1⋅4) 107 (14⋅3)
Missing 9 (0⋅3) 0 (0) 0 (0) 1 (0⋅1) 8 (1⋅1)
Histological type
SSM 1739 (54⋅7) 204 (51⋅3) 762 (70⋅4) 307 (32⋅2) 466 (62⋅4)
NM 885 (27⋅8) 134 (33⋅7) 204 (18⋅9) 353 (37⋅0) 194 (26⋅0)
ALM 93 (2⋅9) 10 (2⋅5) 39 (3⋅6) 23 (2⋅4) 21 (2⋅8)
LMM 139 (4⋅4) 5 (1⋅3) 42 (3⋅9) 75 (7⋅9) 17 (2⋅3)
Other 46 (1⋅4) 9 (2⋅3) 1 (0⋅1) 4 (0⋅4) 32 (4⋅3)
Missing 278 (8⋅7) 36 (9⋅0) 34 (3⋅1) 191 (20⋅0) 17 (2⋅3)
(n=3125) (n=392) (n=1069) (n=926) (n=738)
Breslow thickness (mm)* 1⋅70 (1⋅10–3⋅00) 1⋅90 (1⋅40–2⋅80) 1⋅30 (0⋅88–2⋅40) 2⋅00 (1⋅00–4⋅00) 1⋅70 (1⋅20–2⋅70)
Clark level
I–II 271 (8⋅5) 13 (3⋅3) 60 (5⋅5) 180 (18⋅9) 18 (2⋅4)
III 1230 (38⋅7) 147 (36⋅9) 400 (37⋅0) 479 (50⋅3) 204 (27⋅3)
IV 1354 (42⋅6) 188 (47⋅2) 569 (52⋅6) 219 (23⋅0) 378 (50⋅6)
V 140 (4⋅4) 18 (4⋅5) 31 (2⋅9) 41 (4⋅3) 50 (6⋅7)
Missing 185 (5⋅8) 32 (8⋅0) 22 (2⋅0) 34 (3⋅6) 97 (13⋅0)
Ulceration
No 2264 (71⋅2) 242 (60⋅8) 874 (80⋅8) 604 (63⋅4) 544 (72⋅8)
Yes 788 (24⋅8) 92 (23⋅1) 182 (16⋅8) 339 (35⋅6) 175 (23⋅4)
Missing 128 (4⋅0) 64 (16⋅1) 26 (2⋅4) 10 (1⋅0) 28 (3⋅7)
Mitosis
No 39 (1⋅2) 11 (2⋅8) 0 (0) 0 (0) 28 (3⋅7)
Yes 112 (3⋅5) 59 (14⋅8) 0 (0) 0 (0) 53 (7⋅1)
Missing 3029 (95⋅3) 328 (82⋅4) 1082 (100) 953 (100) 666 (89⋅2)
(n=3039) (n=397) (n=1072) (n=823) (n=747)
Total no. of SNs* 1 (1–2) 2 (1–2) 1 (1–2) 1 (1–1) 2 (2–3)
Multiple SN fields
No 2768 (87⋅0) 337 (84⋅7) 918 (84⋅8) 953 (100) 560 (75⋅0)
Yes 412 (13⋅0) 61 (15⋅3) 164 (15⋅2) 0 (0) 187 (25⋅0)
Values in parentheses are percentages unless indicated otherwise; *values are median (i.q.r.). †Based on 741 patients. EORTC, European Organization for
Research and Treatment of Cancer; SSM, superficial spreading melanoma; NM, nodular melanoma; ALM, acral lentiginous melanoma; LMM, lentigo
maligna melanoma; SN, sentinel node.
multivariable backward selection. Linear predictor values
(the sum of truncated predictor values times their predictor
effects) were scaled and rounded to a risk score with integer
values between 0 and 100. Because recurrence and MSM
are strongly related, the final recurrence prediction model
based on data from all four EORTC centres was used as a
basis for predicting MSM, where the baseline hazard and
the slope of the recurrence prediction model were cali-
brated to MSM22. The advantage of this approach is that it
is possible to obtain a unique risk score for each patient that
translates into probabilities of both outcomes of interest:
recurrence and MSM. This is in contrast to developing
two independent prediction models that result in two inde-
pendent risk scores with corresponding probabilities. To
test the validity of this approach, the performance of an
independently developedMSMpredictionmodel was com-
pared with that of the calibrated MSM prediction model.
The absolute risk prediction of each of the two outcomes
was plotted against the risk score. To reduce the overes-
timation of events occurring in patients with extremely
high scores, the score was truncated at an integer of 15,
which corresponded to the 95th percentile of score distri-
bution in the cohort. Model performance was assessed by
examining discrimination and calibration. Discrimination
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Table 2 Outcomes and follow-up by centre
EORTC centres
All (n=3180) Centre 1 (n=398) Centre 2 (n=1082) Centre 3 (n=953) Centre 4 (n= 747)
Recurrence
Yes 496 (15⋅6) 91 (22⋅9) 94 (8⋅7) 191 (20⋅0) 120 (16⋅1)
No 2684 (84⋅4) 307 (77⋅1) 988 (91⋅3) 762 (80⋅0) 627 (83⋅9)
Recurrence type†
Locoregional 142 (28⋅6) 34 (37) 25 (27) 38 (19⋅9) 45 (37⋅5)
Regional nodal 122 (24⋅6) 14 (15) 32 (34) 48 (25⋅1) 28 (23⋅3)
Distant 194 (39⋅1) 43 (47) 37 (39) 67 (35⋅1) 47 (39⋅2)
Unknown 38 (7⋅7) 0 (0) 0 (0) 38 (19⋅9) 0 (0)
Additional surgery‡
Yes 13 (0⋅4) 13 (3⋅3) 0 (0) 0 (0) 0 (0)
n.r. 3167 (99⋅6) 385 (96⋅7) 1082 (100) 953 (100) 747 (100)
Radiotherapy
Yes 24 (0⋅8) 24 (6⋅0) 0 (0) 0 (0) 0 (0)
n.r. 3156 (99⋅2) 374 (94⋅0) 1082 (100) 953 (100) 747 (100)
Chemotherapy
Yes 12 (0⋅4) 12 (3⋅0) 0 (0) 0 (0) 0 (0)
n.r. 3168 (99⋅6) 386 (97⋅0) 1082 (100) 953 (100) 747 (100)
Novel therapy§
Yes 22 (0⋅7) 16 (4⋅0) 0 (0) 0 (0) 6 (0⋅8)
n.r. 3158 (99⋅3) 382 (96⋅0) 1082 (100) 953 (100) 741 (99⋅2)
Duration of follow-up for survivors (months)* 61 (29–99) 94 (59–131) 33 (12–68) 87 (50–127) 57 (35–84)
Status
No evidence of disease 2736 (86⋅0) 318 (79⋅9) 984 (90⋅9) 786 (82⋅5) 648 (86⋅7)
Alive with disease 90 (2⋅8) 12 (3⋅0) 23 (2⋅1) 20 (2⋅1) 35 (4⋅7)
Died from disease 277 (8⋅7) 56 (14⋅1) 41 (3⋅8) 139 (14⋅6) 41 (5⋅5)
Died from other cause 75 (2⋅4) 12 (3⋅0) 34 (3⋅1) 8 (0⋅8) 21 (2⋅8)
n.r. 2 (0⋅1) 0 (0) 0 (0) 0 (0) 2 (0⋅3)
Values in parentheses are percentages unless indicated otherwise; *values are median (i.q.r.). †Defined as follows: locoregional recurrence only (for
example in-transit metastasis or satellites), regional nodal recurrence similar to sentinel node basin (with or without concurrent locoregional disease) and
distant recurrence (with or without concurrent locoregional and/or regional nodal disease). ‡Includes resection of metastases or lymph node dissection.
§Includes vaccines, targeted therapy and immunotherapy. EORTC, European Organization for Research and Treatment of Cancer; n.r., not reported.
was measured using the concordance index (c-index); the
closer the c-index is to 1, the better the discrimination, and
a value of 0⋅5 indicates that the model is no better than
chance23. Calibration was assessed visually by plotting the
predicted probability against the actual observed frequency
in quintiles of predicted recurrence and melanoma-specific
mortality. A 45∘ line indicates perfect calibration (when
the predictive value of the model perfectly matches the
patient’s actual risk). Any deviation above or below the 45∘
line indicates underprediction or overprediction respec-
tively. To evaluate the generalizability of the model across
different centres, an internal–external cross-validation was
performed in which the model was fitted using data from
three centres and validated in the centre that was left out24.
A nomogram was developed for graphical presentation of
the models. All statistical tests were two-sided with a sta-
tistical significance level set at P< 0⋅050. Statistic analyses
were performed with IBM SPSS® 22.0 (IBM, Armonk,
New York, USA) and R version 3.3.2 (R Foundation for
Statistical Computing, Vienna, Austria).
Results
From the 3220 patients identified with melanoma and
negative SNs, 3180 were eligible for inclusion in the
present study. Patients were excluded due to duplicates
(9), urogenital melanoma (8), in situ melanoma (7), SLNB
for recurrent disease (2), missing data (4), or discrepancy
between date of recurrence and date of diagnosis and/or
SLNB (10). Baseline patient and tumour characteristics
for all patients and per EORTC centre are shown in
Table 1.
Median duration of follow-up for all survivors was 61
(i.q.r. 29–99) months. Recurrence occurred in 496 patients
(15⋅6 per cent). TheDFS rate at 5 and 10 years was 86⋅7(s.e.
0⋅7) and 72⋅8(1⋅3) per cent respectively. Some 277 patients
(8⋅7 per cent) died from melanoma. The MSS rate at 5 and
10 years was 91⋅5(0⋅6) and 84⋅8(1⋅0) per cent respectively.
Details of outcome and follow-up for all patients and per
EORTC centre are depicted in Table 2.
Table 3 gives the results of the multivariable Cox model
for recurrence including all nine candidate variables. After
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Table 3 Multivariable Cox analysis of recurrence
Hazard ratio P
Age (i.q.r. 67 versus 44 years) 1⋅06 (0⋅82, 1⋅36) 0⋅920
Sex
F 1⋅00 (reference)
M 1⋅20 (0⋅99, 1⋅45) 0⋅065
Breslow thickness (i.q.r. 3⋅0
versus 1⋅1mm)
2⋅47 (1⋅94, 3⋅13) < 0⋅001
Ulceration
No 1⋅00 (reference)
Yes 1⋅84 (1⋅50, 2⋅26) < 0⋅001
Clark level 0⋅005
I–II 1⋅00 (reference)
III 1⋅59 (0⋅97, 2⋅61)
IV 1⋅68 (1⋅02, 2⋅75)
V 2⋅70 (1⋅51, 4⋅80)
Anatomical location 0⋅001
Arm 1⋅00 (reference)
Leg 1⋅38 (1⋅03, 1⋅87)
Trunk 1⋅54 (1⋅15, 2⋅07)
Head and neck 2⋅12 (1⋅45, 3⋅11)
Histology 0⋅336
SSM 1⋅00 (reference)
NM 1⋅18 (0⋅93, 1⋅49)
ALM 1⋅53 (0⋅94, 2⋅51)
LMM 1⋅25 (0⋅77, 2⋅03)
Other 0⋅89 (0⋅45, 1⋅79)
No. of SNs (i.q.r. 2 versus 1) 1⋅06 (0⋅87, 1⋅29) 0⋅800
Multiple SN fields
No 1⋅00 (reference)
Yes 1⋅15 (0⋅82, 1⋅62) 0⋅411
Values in parentheses are 95 per cent confidence intervals. SSM,
superficial spreading melanoma; NM, nodular melanoma; ALM, acral
lentiginous melanoma; LMM, lentigo maligna melanoma; SN, sentinel
node.
backwards selection and manual exclusion of Clark level
(due to limited additional effect and current clinical prac-
tice), the final model for recurrence included three inde-
pendent prognostic factors: ulceration, anatomical site and
Breslow thickness (Table 4). The non-linearity of Breslow
thickness was highly significant (P< 0⋅001) and well repre-
sented by logarithmic transformation. The c-index for the
final recurrence model was 0⋅74 (95 per cent c.i. 0⋅71 to
0⋅76). In cross-validation, the c-index for a model based
on three centres and applied to the centre that was left
out ranged from 0⋅70 to 0⋅77. The additional prognostic
value of mitotic rate (at least 1 mitosis/mm2 present in
112 of 151 observations), tested in a model with the lin-
ear predictor as an offset, was not significant (P= 0⋅678).
The recurrence model was reasonably calibrated across
the four centres in cross-validation (Fig. S1, supporting
information).
The association between the linear predictors of recur-
rence and MSM was even stronger (calibration slope 1⋅10,
95 per cent c.i. 0⋅96 to 1⋅24). The c-index for the calibrated
Table 4 Final model for recurrence
Hazard ratio P
Breslow thickness (i.q.r. 3⋅0 versus 1⋅1mm) 2⋅22 (1⋅97, 2⋅51) < 0⋅001
Ulceration
No 1⋅00 (reference)
Yes 1⋅85 (1⋅52, 2⋅25) < 0⋅001
Anatomical site
Arm 1⋅00 (reference)
Leg 1⋅35 (1⋅01, 1⋅81) 0⋅044
Trunk 1⋅55 (1⋅17, 2⋅05) 0⋅002
Head and neck 2⋅39 (1⋅66, 3⋅44) < 0⋅001
Values in parentheses are 95 per cent confidence intervals.
Table 5 Final model for melanoma-specific mortality
Hazard ratio P
Breslow thickness (i.q.r. 3⋅0 versus 1⋅1mm) 2⋅37 (2⋅03, 2⋅78) < 0⋅001
Ulceration
No 1⋅00 (reference)
Yes 2⋅11 (1⋅62, 2⋅75) < 0⋅001
Anatomical site
Arm 1⋅00 (reference)
Leg 0⋅97 (0⋅66, 1⋅44) 0⋅881
Trunk 1⋅70 (1⋅18, 2⋅44) 0⋅004
Head and neck 1⋅80 (1⋅07, 3⋅03) 0⋅028
Values in parentheses are 95 per cent confidence intervals.
MSM model was 0⋅76 (0⋅73 to 0⋅79). In cross-validation,
the c-index for a calibrated model based on three centres
applied to the centre that was left out ranged from 0⋅73
to 0⋅80. The calibrated model was reasonably calibrated
across the four centres in cross-validation (Fig. S2, support-
ing information). The performance of this calibratedMSM
prediction model, based on the baseline hazard and the
slope of the recurrence model, was similar to that of the
independently developed MSM prediction model (c-index
0⋅77, 0⋅74 to 0⋅80) (Table 5).
A three-item risk score was developed, assigning points
to each prognostic factor based on the magnitude of asso-
ciation with recurrence. A nomogram to calculate the
score and the risk of recurrence and MSM is presented
in Fig. 1. The scores were divided into three classes based
on the score distribution (each consisting of approximately
one-third of the cohort): low risk, score 0–6; intermedi-
ate risk, score 7–9; high risk, score 10 or more (Fig. 1).
For recurrence, these risk classes correspond to the fol-
lowing probabilities: low risk, 1⋅6–8⋅2 per cent; interme-
diate risk, 11⋅0–18⋅0 per cent; high risk, 23⋅0 per cent
or above. For MSM, these risk classes correspond to the
following probabilities: low risk, 0⋅5–3⋅2 per cent; inter-
mediate risk, 4⋅4–8⋅0 per cent; high risk, 11⋅0 per cent
or more.
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Fig. 1 The curves refer to predicted recurrence or melanoma-specific mortality (MSM) at 5 years. The histogram refers to the risk score
distribution in the cohort; each bar represents the proportion of patients in the cohort that was assigned that specific score. The
histogram was divided in tertiles: light pink bars, first tertile (low risk); medium pink bars, second tertile (intermediate risk); dark pink
bars, third tertile (high risk). The nomogram incorporates three factors: ulceration, anatomical location and Breslow thickness. To
calculate an individual’s probability of 5-year recurrence and MSM, values for the prognostic factors must be determined first (for
example: ulceration; leg; Breslow thickness 2⋅5mm). Second, for each value the corresponding points can be obtained by drawing a line
from each value towards the points axis (in example: 2, 1 and 7 points respectively). Third, the points must be added up to obtain the
total risk score (in example: risk score of 10). Finally, the 5-year recurrence and MSM probability can be read by moving vertically from
the x-axis (total risk score) to the predicted risk curves and corresponding probabilities on the left y-axis (for example: 23⋅0 per cent for
recurrence and 11⋅0 per cent for MSM). The percentage of patients in the entire population (3180) that also had a total risk score of 10
can be determined from the histogram, as well as the corresponding percentage of patients on the right y-axis (for example: 17⋅5 per
cent)
Discussion
Patients with melanoma are staged according to the AJCC
staging system, based on TNM criteria12. Within these
stage groupings there is still marked prognostic hetero-
geneity, and several clinical prognostic tools have been
developed to improve predictive accuracy25. None of these
tools focuses specifically on outcomes in patients with neg-
ative SNs, and most predict only survival25,26.
The present study developed and validated a nomogram
to predict recurrence andMSM in patients with melanoma
and negative SNs. Focusing on specifically these patients
is important for several reasons. They comprise a large
group with highly varying prognosis, who are gener-
ally offered regular surveillance examinations with the
intent to detect early (locoregional) recurrence. Follow-up
strategies vary, but usually focus on regular clinical exam-
ination for 5–10 years15,19. Some guidelines support a
one-off follow-up visit with instructions for subsequent
self-examination after treatment for stage IA melanoma27.
The recurrence rate for stage IA disease is reported to be
5 per cent28.
Besides personalized outcome prediction, the nomogram
could be used to group patients. In the present study
population, approximately one-third of patients with a neg-
ative SN had an 8⋅2 per cent or less predicted probability
of recurrence (risk score 6 or less). Surveillance strategies
could be reduced in these patients, particularly as most
recurrences are self-detected, and less frequent follow-up
seems to have no effect on recurrence and self-detection
rates, and no adverse effects29,30.
However, a 5-year risk of relapse of 48 per cent has been
reported for stage IIIA melanoma31. In the present study
population, approximately one-fifth had a 30 per cent or
greater predicted recurrence probability (risk score 11 or
more). Surveillance strategies could be intensified in these
patients, or they could be considered for adjuvant therapy
(trials). The present nomogram could aid in designing
clinical trials by defining inclusion criteria, or help gain
better equivalence between study arms.
In the current era of effective novel therapies in both
the adjuvant and therapeutic setting it is highly relevant to
focus on negative SN melanoma, as it is likely that most
patients with negative SNs will not be offered adjuvant
© 2018 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS
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therapy before first recurrence. Mortality predictions in
these patients might be partly affected in the present study,
as those who developed recurrent disease after 2011 were
eligible to receive effective therapy.
This study has important strengths, including its large
size, widely available and easily ascertainable characteris-
tics, multicentre composition, and outcomes that are of
interest to both clinicians and patients. In multivariable
analysis, ulceration, anatomical site and Breslow thickness
proved to be significant independent prognostic factors, in
concordance with previous reports10,11,13,16,32. Clark level
is no longer part of the seventh AJCC staging edition for
melanoma because it was shown not to be an independent
prognostic factor when corrected for mitotic rate17. As
its effect was marginal in the multivariable model for
recurrence, Clark level was excluded manually. All patients
were treated at multidisciplinary high-volume Euro-
pean melanoma centres that applied similar international
guideline criteria. This minimizes variability in the inter-
pretation of results and, as generally a policy of centralized
referral of patients with melanoma eligible for SLNB is
recommended, the cohort is likely to be representative
of the European melanoma population with a negative
SN. Another strength of the nomogram is the model
performance. Discrimination and calibration were good
for both the recurrence model and the calibrated model for
MSM. The performance of the calibrated model for MSM
was comparable to the independently developed model for
MSM, indicating the validity of the applied approach. Fur-
thermore, the models were successful in cross-validation
and showed good agreement between prediction and actual
observation. Validation of the nomogram is essential to
avoid overfitting and to determine generalizability33. In
the present study, the prediction models were validated
using the recommended internal–external validation pro-
cedure. One centre at a time was left out to cross-validate
a model developed in the other centres; as this split was
not random, it qualifies as external validation24. Pre-
vious prediction models did not focus on SN-negative
melanoma25,26. The AJCC online prognostic calcula-
tor focused on localized melanoma but included both
clinical and pathological stage I–II disease (thus also
patients who did not undergo SLNB) and predicted
only melanoma-specific survival34. In addition, all tools
but one predict survival (disease-specific or overall)25,35.
The online Sunbelt predictor (MelanomaCalculator
.com) included patients staged by SLNB (both positive
and negative) and calculates overall survival, as well as
DFS and locoregional recurrence-free survival; however,
only the methodology for predicting overall survival was
published36.
This study also has several limitations. The first is the ret-
rospective design, which has inherent biases. In addition,
other prognostic factors such as regression or lymphatic
invasion37,38 could not be incorporated in the present mod-
els due to insufficient data. They could be incorporated
in next-generation nomograms. Another variable shown to
have an independent prognostic effect is mitotic rate17,32.
The prognostic effect of mitotic rate was tested by intro-
ducing it as an offset term, but it was not significant. This
study did not perform competing-risk analysis, which has
been done before26. Consequently the predictions are an
overestimate of the actual risk, but, owing to relatively few
competing events, this overestimation is expected to be
limited. Presently, there is no online version of the nomo-
gram, but it is hoped to have this available soon.
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